Spanish stock market presents InKemia IUCT as candidate to European Commission European Small & Midcap Awards
The Catalan biotechnology group, which has been traded on the MAB for the past six months, will compete in the most innovative company category.
By Biocat
Biotechnology group InKemia IUCT, based in Mollet del Vallès, has been chosen to represent the Spanish stock market at the European Small & Midcap Awards in the most innovative company category. To participate in these awards, stock markets in each EU country select companies in each of the four categories: most innovative company, most traded company, most internationally minded company and rising star.
The InKemia IUCT group closed 2012 with profit double that seen the previous year, for a total of €1,030 millions
The awards are organized by the European Commission’s Directorate General for Enterprise and Industry and serve to recognize and boost visibility of the best SME in each category. To opt for this award, however, the company must have been traded for at least 3 years on the stock market. Likewise, the company’s evolution in terms of finance, trading and the category in question will be taken into account.
This news was announced just six months after the InKemia IUCT group went public on the Alternative Stock Market (MAB), making it the second Catalan company to do so (after AB-Biotics). The Catalan group of biotechnology and high-technology SMEs continues to post positive growth, demonstrated by their recent announcement of a €2.5-millions capital increase to boost international expansion and the close of the 2012 fiscal year with profit of €1,030 millions, up 110% from 2011.
- Related news (20/12/2012)
- Related news (25/3/2013)